Maseda, Emilio
Martín-Loeches, Ignacio
Zaragoza, Rafael
Pemán, Javier
Fortún, Jesús
Grau, Santiago
Aguilar, Gerardo
Varela, Marina
Borges, Marcio
Giménez, María-José
Rodríguez, Alejandro
Article History
Received: 23 August 2023
Accepted: 28 September 2023
First Online: 3 October 2023
Declarations
:
: Not applicable.
: Not applicable.
: EM and MB have received consultancy fees and payment for lectures from Astellas. Pharma S.A. (Madrid, Spain), Pfizer, Novartis, Angellini, and Merck Sharp and Dohme; IM-L reports grants from Grifols, consulting fees from Gilead and MSD, lecture honoraria from MSD, Gilead and Mundipharma, and advisory board and lectures for Pfizer, MSD and Menarini, outside the submitted work; RZ has received financial compensation for consulting/speaking/researching from Gilead and MSD; JP has received financial compensation for consulting/speaking/researching from Pfizer, Gilead and MSD; JF has received financial compensation for consulting/speaking/researching from Pfizer, Gilead, MSD, Shionogi, Astellas, Novartis, Roche; SG and MV declare no conflict of interest; GA received financial support for speaking at meetings organised on behalf of Pfizer, Merck Sharp and Dohme (MSD) and Gilead; M-JG received grants from Gilead S.L and Tedec-Meiji Pharma for PK/PD analysis and consultancy; and AR has received financial compensation for speaking from Pfizer, Gilead, MSD, Shionogi and BioMerieux.